Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma

Faculty of 1000 evaluation for Phase II Open Label Study of the oral VEGF-Receptor inhibitor PTK787/ZK222584 (Vatalanib) in Adult Patients with Refractory or Relapsed Diffuse Large B Cell Lymphoma.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.717995403.793474246 ◽

2013 ◽

Author(s):

Nicolas Mounier

Keyword(s):

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Vegf Receptor ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Large B Cell Lymphoma ◽

Large B Cell ◽

Receptor Inhibitor

Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access (EA) and Commercial out-of-Specification (OOS) Product

Transplantation and Cellular Therapy ◽

10.1016/s2666-6367(21)00524-8 ◽

2021 ◽

Vol 27 (3) ◽

pp. S408

Author(s):

Caron A. Jacobson ◽

Frederick L. Locke ◽

David B. Miklos ◽

Julie M. Vose ◽

Yi Lin ◽

...

Keyword(s):

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Expanded Access ◽

Large B Cell Lymphoma ◽

Phase 2, open-label study of CUDC-907 with and without rituximab in patients with relapsed/refractory MYC-altered diffuse large B-cell lymphoma.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps7579 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS7579-TPS7579

Author(s):

Daniel Jeffrey Landsburg ◽

Kevin Kelly ◽

Jaye Viner ◽

Jing Wang ◽

Lucy Gong ◽

...

Keyword(s):

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Phase 2 ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Large B Cell Lymphoma ◽

A phase I, open-label study of GSK2816126, an enhancer of zeste homolog 2 (EZH2) inhibitor, in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (tFL), other non-Hodgkin’s lymphomas (NHL), multiple myeloma (MM) and solid tumor.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps2595 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS2595-TPS2595 ◽

Cited By ~ 6

Author(s):

Timothy Anthony Yap ◽

Peter W. M. Johnson ◽

Jane Winter ◽

John Leonard ◽

Lisa Giulino-Roth ◽

...

Keyword(s):

Multiple Myeloma ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Large B Cell Lymphoma ◽

Hodgkin's Lymphomas ◽

Transformed Follicular Lymphoma ◽

A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-16-2818 ◽

2017 ◽

Vol 23 (15) ◽

pp. 4127-4137 ◽

Cited By ~ 64

Author(s):

Myron S. Czuczman ◽

Marek Trněný ◽

Andrew Davies ◽

Simon Rule ◽

Kim M. Linton ◽

...

Keyword(s):

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Large B Cell Lymphoma ◽

High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy

European Journal Of Haematology ◽

10.1111/ejh.12005 ◽

2012 ◽

Vol 89 (5) ◽

pp. 395-402 ◽

Cited By ~ 6

Author(s):

Sari Riihijärvi ◽

Heidi Nurmi ◽

Harald Holte ◽

Magnus Björkholm ◽

Øystein Fluge ◽

...

Keyword(s):

Cell Lymphoma ◽

B Cell Lymphoma ◽

High Serum ◽

Vascular Endothelial ◽

Factor Level ◽

Adverse Prognostic Factor ◽

Large B Cell Lymphoma ◽

Dose Dense ◽

Abnormal vascular endothelial growth factor protein expression may be correlated with poor prognosis in diffuse large B-cell lymphoma: A meta-analysis

Journal of Cancer Research and Therapeutics ◽

10.4103/0973-1482.146086 ◽

2016 ◽

Vol 12 (2) ◽

pp. 605 ◽

Cited By ~ 3

Author(s):

Ai-Chun Liu ◽

Li Jiang ◽

JiangHong Sun ◽

Li-Na Quan ◽

Yu-Yang Tian ◽

...

Keyword(s):

Growth Factor ◽

Poor Prognosis ◽

Cell Lymphoma ◽

Meta Analysis ◽

B Cell Lymphoma ◽

Vascular Endothelial ◽

Large B Cell Lymphoma ◽

Primary cutaneous diffuse large B-cell lymphoma, leg type, with expression of both vascular endothelial growth factor and its receptors

Leukemia Research ◽

10.1016/j.leukres.2009.05.019 ◽

2009 ◽

Vol 33 (11) ◽

pp. e181-e183 ◽

Cited By ~ 2

Author(s):

Shoko Nakayama ◽

Taiji Yokote ◽

Kichinosuke Kobayashi ◽

Yuji Hirata ◽

Toshikazu Akioka ◽

...

Keyword(s):

Growth Factor ◽

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Vascular Endothelial ◽

Large B Cell Lymphoma ◽

The Interplay Between C-Myc Oncogene Expression and Circulating Vascular Endothelial Growth Factor (sVEGF), Its Antagonist Receptor, Soluble Flt-1 in Diffuse Large B Cell Lymphoma (DLBCL): Relationship to Patient Outcome

Leukemia & Lymphoma ◽

10.1080/10428190310001607151 ◽

2004 ◽

Vol 45 (3) ◽

pp. 499-506 ◽

Cited By ~ 15

Author(s):

S Aref ◽

M Mabed ◽

K Zalata ◽

M Sakrana ◽

H El Askalany

Keyword(s):

Patient Outcome ◽

Growth Factor ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Vascular Endothelial ◽

Myc Oncogene ◽

Large B Cell Lymphoma ◽

Microvessel Density and Expression of Vascular Endothelial Growth Factor and Its Receptors in Diffuse Large B-Cell Lymphoma Subtypes

American Journal Of Pathology ◽

10.2353/ajpath.2007.060901 ◽

2007 ◽

Vol 170 (4) ◽

pp. 1362-1369 ◽

Cited By ~ 59

Author(s):

Dita Gratzinger ◽

Shuchun Zhao ◽

Robert J. Marinelli ◽

Amy V. Kapp ◽

Robert J. Tibshirani ◽

...

Keyword(s):

Growth Factor ◽

B Cell ◽

Microvessel Density ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Vascular Endothelial ◽

Large B Cell Lymphoma ◽